Endocyte Inc. (ECYT) Financials Nov 18, 2014, 6:48
Post# of 250665
Posted On: 11/18/2014 10:10:45 PM
Endocyte Inc. (ECYT) Financials Nov 18, 2014, 6:48 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Endocyte Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 3M 0 191,023 34.68M 64.87M
Cost of Goods Sold (COGS) incl. D&A 281,890 260,571 262,518 - -
COGS excluding D&A 50,000 0 0 - -
Depreciation & Amortization Expense 231,890 260,571 262,518 358,367 674,725
Depreciation - - - 358,367 674,725
Amortization of Intangibles - - - 0 0
Gross Income 2.72M (260,571) (71,495) - -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 18.46M 20.34M 38.57M 50.37M 82.54M
Research & Development 14.8M 14.56M 28.83M 35.67M 57.9M
Other SG&A 3.65M 5.78M 9.74M 14.7M 24.64M
Other Operating Expense 0 0 0 0 0
Unusual Expense - - 546 0 0
EBIT after Unusual Expense - - (546) 0 0
Non Operating Income/Expense 118,988 1.56M (35,920) (947,834) (153,702)
Non-Operating Interest Income 49,315 7,683 129,449 327,745 465,505
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 1.44M 1.06M 1.99M 628,993 2,458
Gross Interest Expense 1.44M 1.06M 1.99M 628,993 2,458
Interest Capitalized - - 0 0 0
Pretax Income (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
Minority Interest Expense 0 0 0 0 0
Net Income (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
EPS (Basic) (0.55) (0.73) (1.40) (0.48) (0.50)
Basic Shares Outstanding 24.63M 27.7M 29M 35.86M 36.04M
EPS (Diluted) (0.55) (0.73) (1.40) (0.48) (0.50)
Diluted Shares Outstanding 24.63M 27.7M 29M 35.86M 36.04M
EBITDA (15.51M) (20.34M) (38.37M) (15.68M) (17.67M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Endocyte Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 3M 0 191,023 34.68M 64.87M
Cost of Goods Sold (COGS) incl. D&A 281,890 260,571 262,518 - -
COGS excluding D&A 50,000 0 0 - -
Depreciation & Amortization Expense 231,890 260,571 262,518 358,367 674,725
Depreciation - - - 358,367 674,725
Amortization of Intangibles - - - 0 0
Gross Income 2.72M (260,571) (71,495) - -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 18.46M 20.34M 38.57M 50.37M 82.54M
Research & Development 14.8M 14.56M 28.83M 35.67M 57.9M
Other SG&A 3.65M 5.78M 9.74M 14.7M 24.64M
Other Operating Expense 0 0 0 0 0
Unusual Expense - - 546 0 0
EBIT after Unusual Expense - - (546) 0 0
Non Operating Income/Expense 118,988 1.56M (35,920) (947,834) (153,702)
Non-Operating Interest Income 49,315 7,683 129,449 327,745 465,505
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 1.44M 1.06M 1.99M 628,993 2,458
Gross Interest Expense 1.44M 1.06M 1.99M 628,993 2,458
Interest Capitalized - - 0 0 0
Pretax Income (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
Minority Interest Expense 0 0 0 0 0
Net Income (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (17.01M) (20.09M) (40.53M) (17.29M) (18.03M)
EPS (Basic) (0.55) (0.73) (1.40) (0.48) (0.50)
Basic Shares Outstanding 24.63M 27.7M 29M 35.86M 36.04M
EPS (Diluted) (0.55) (0.73) (1.40) (0.48) (0.50)
Diluted Shares Outstanding 24.63M 27.7M 29M 35.86M 36.04M
EBITDA (15.51M) (20.34M) (38.37M) (15.68M) (17.67M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)